Previous close | 5,335.00 |
Open | 5,335.00 |
Bid | 5,489.00 x N/A |
Ask | 5,503.00 x N/A |
Day's range | 5,301.00 - 5,520.00 |
52-week range | 3,566.00 - 5,520.00 |
Volume | |
Avg. volume | 4,318,716 |
Market cap | 10.55T |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 52.63 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 60.00 (1.09%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.